| h-4c3210de | Ancestry-Adapted Mitochondrial Rescue Therapy | 0.56 | 0.55 | PPARGC1A, NRF1, TFAM | proposed | 2026-04-12 | SDA-2026-04-04-gap-debate-20260403-222549-20260402 |
| h-e14a97bf | Timed Senolytic Therapy Eliminates p16^Ink4a/p21^Cip1-Senescent Microglia to Pre | 0.56 | 0.72 | CDKN2A (p16^Ink4a), CDKN1A (p21^Cip1/Waf1) | promoted | 2026-04-15 | SDA-2026-04-15-gap-pubmed-20260411-075425-2feffb0c |
| h-763d9c478e | P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming | 0.56 | 0.45 | P2RX7/NLRP3 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062039-3b945972 |
| h-ba3a948a | Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators | 0.56 | 0.60 | CX3CR1 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-691b42f1 |
| h-b3e97952 | C9orf72-SMCR8-WDR41 Complex Dysfunction in C9-ALS Rescued by PIKFYVE Inhibition | 0.56 | 0.50 | C9orf72/SMCR8/RAB7A/PIKFYVE | proposed | 2026-04-13 | SDA-2026-04-13-gap-pubmed-20260410-143119-8ae42941 |
| h-2263e00831 | Blood-Brain Barrier Pericyte-to-Mesenchymal Transition Drives Vascular Collapse | 0.56 | 0.62 | PDGFRβ, SNAI2/SLUG, AQP4 | proposed | 2026-05-03 | SDA-2026-05-03-gap-test-20260425-224949 |
| h-9ea3d9ea8c | TFEB-Mediated Lysosomal Biogenesis Restoration for GRN Haploinsufficiency FTD | 0.56 | 0.68 | TFEB/GRN | proposed | 2026-04-28 | SDA-2026-04-28-gap-test-20260425-224949 |
| h-7befe3ab58 | SIRT1 Activation Suppresses C9orf72-Mediated Neurodegeneration | 0.56 | 0.58 | SIRT1 | proposed | 2026-04-28 | SDA-TEST-PREREG-003 |
| h-36d21444fd | G2019S Amplifies Lysosomal Volume-Sensing Through Membrane Microdomain Partition | 0.56 | 0.45 | LRRK2,PI4P | proposed | 2026-04-26 | SDA-2026-04-23-gap-debate-20260417-033119-54941818 |
| h-fa11c9bd1e | HBOT (2.0 ATA, 60 min) activates TFEB-mediated autophagy-lysosome pathway to acc | 0.56 | 0.58 | TFEB (TFE2) | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260410-181340-8acb24dc-debate |
| h-5186801ea0 | SIRT3 loss creates a mitochondrial acetylation-stress loop that weakens antioxid | 0.56 | 0.58 | SIRT3; SOD2; IDH2; PPIF | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260410-181140-0af1a353-debate |
| h-2416d8f8d2 | Synaptic protection via microglial/complement normalization | 0.56 | 0.55 | TREM2/complement cascade | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260410-150544-e3a2eab9-debate |
| h-0f37721539 | BBB leak induces secondary pericyte senescence through TGF-beta-dominant stress | 0.56 | 0.42 | TGFB1, TGFBR2, SMAD2, SMAD3 | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-de5dfc4391 |
| h-71cd255f48 | Direct neuronal HDAC inhibition is unlikely to mediate therapeutic alpha-synucle | 0.56 | 0.71 | HDAC1/HDAC2 | proposed | 2026-04-24 | SDA-2026-04-25-gapdebate-18cce7b525 |
| h-a25bd0a027 | H3: Reelin Signaling Deficiency Uncouples Layer II Neurons from Grid Cell Coupli | 0.56 | 0.52 | RELN, LRP8, GSK3B | proposed | 2026-04-22 | SDA-2026-04-02-gap-ec-layer2-vulnerability |
| h-37ead784be | TFEB Activation Clears Tau-Loaded Endolysosomal Compartments, Preventing Release | 0.56 | 0.58 | TFEB | proposed | 2026-04-22 | SDA-2026-04-04-gap-20260404-052358 |
| h-567197b279 | Persistent γH2AX+53BP1 Foci with DREAM Complex Activation Defines Irreversibly A | 0.56 | 0.65 | H2AFX (γH2AX), TP53BP1, DREAM complex (LIN9, LIN37, RBL2, E2 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062101-6af4ba5f |
| h-ff5951ff09 | Post-Translational Modification Codes Determine Interaction Specificity | 0.56 | 0.55 | G3BP1, PRMT1, PRMT5, ATM, ATR | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041428-53b81741 |
| h-e5f17434c3 | AQP4 Autoantibodies in NMOSD Cause Bystander Oligodendrocyte Injury via Metaboli | 0.56 | 0.52 | AQP4; SLC16A1 (MCT1); SLC16A3 (MCT4) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041445-ce0abc1e |
| h-cfcf4d4c0d | Temporal cGAS-STING Activation Stage-Specific Therapeutic Targeting | 0.56 | 0.48 | STING (TMEM173) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062141-fc60e018 |
| h-9f5ce0a588 | MOG-IgG induces spinal cord demyelination through Fcγ receptor-dependent macroph | 0.56 | 0.58 | MOG, FCGR1A, FCGR3A, FCGR2A, SYK, IRAK4 | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-062111-e3e328bf |
| h-dd53a5c2 | GCH1/BH4 Axis Stabilization for Dual Ferroptosis and Mitochondrial Protection | 0.56 | 0.56 | GCH1, BH4 | proposed | 2026-04-16 | SDA-2026-04-16-gap-ferroptosis-als-d2fb6bf796ed |
| h-6be901fb | TRPML1-PINK1/Parkin Axis Coordinates Mitophagy with Lysosomal Biogenesis | 0.56 | 0.58 | MCOLN1, PINK1, PARK2, TFEB, LRRK2 | promoted | 2026-04-16 | SDA-2026-04-16-gap-debate-20260410-113045-27c7b314 |
| h-b5723774 | Complement C1q Suppression as Mechanism Linking Exercise Plasma to PV Interneuro | 0.56 | 0.65 | C1QA | promoted | 2026-04-14 | SDA-2026-04-14-gap-pubmed-20260410-191046-15921012 |
| h-var-1a318725cd | Real-time closed-loop transcranial focused ultrasound targeting PVALB interneuro | 0.56 | 0.71 | PVALB | promoted | 2026-04-21 | SDA-2026-04-03-26abc5e5f9f2 |
| h-e9b162c4 | AMPK Activation to Restore Autophagy and Clear α-Synuclein Aggregates | 0.56 | 0.40 | | proposed | 2026-04-18 | SDA-2026-04-17-gap-pubmed-20260410-145520-5692b02e |
| h-0343d1825e | Astrocyte Reactivity Subtype Targeting GABA Synthesis | 0.56 | 0.55 | GAD1 | proposed | 2026-04-28 | SDA-2026-04-28-gap-methodol-20260427-041425-9e73b245 |
| h-83efeed6 | Circadian-Gated Maresin Biosynthesis Amplification | 0.56 | 0.40 | ALOX12 | debated | 2026-04-02 | sda-2026-04-01-gap-014 |
| h-48775971 | Gut-Brain Axis Microbiome Modulation | 0.56 | 0.40 | GPR43, GPR109A | debated | 2026-04-04 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |
| h-da0eec2bdf | Perivascular Dimensionality: GluN2B Control of Thalamocortical vs. Corticopial G | 0.56 | 0.52 | GRIN2B activity pattern; topological glymphatic routing | proposed | 2026-04-28 | SRB-2026-04-28-h-var-e2b5a7e7db |
| h-15d40f8710 | Sticker-Spacer Phase Behavior Determines Recruitment Hierarchy | 0.56 | 0.65 | 53BP1/TP53BP1 | proposed | 2026-04-21 | SDA-2026-04-10-gap-debate-20260410-075026-23501c3c |
| hyp_test_852af3c6 | Test: TREM2 enhances amyloid clearance | 0.56 | 0.33 | TREM2 | proposed | 2026-04-17 | test-hypothesis-fixtures-v1 |
| h-var-e53ee5ba83 | Optogenetic restoration of hippocampal gamma oscillations via channelrhodopsin-2 | 0.56 | 0.71 | PVALB | promoted | 2026-04-21 | SDA-2026-04-03-26abc5e5f9f2 |
| h-var-3fbcfc0e6c | CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Revers | 0.55 | 0.65 | CYP46A1 | proposed | 2026-04-07 | SDA-2026-04-26-trem2-showcase |
| h-eef1be45 | Inhibitory Neuron-Selective WNT Signaling Restoration | 0.55 | 0.30 | WNT3A, CTNNB1, TCF7L2 | proposed | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222543-20260402 |
| h-cd49366c | Profilin-1 Cytoskeletal Checkpoint Enhancement | 0.55 | 0.40 | PFN1 | proposed | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-04a4889c | Dual NF-κB/MMP Inhibition Strategy | 0.55 | 0.56 | NFKB1 | proposed | 2026-04-16 | SDA-2026-04-16-gap-bbb-tjp-20260416041707 |
| h-1dd95a85f3 | Fusing IGFBPL1 to IGF-1 for Receptor-Mediated BBB Transcytosis | 0.55 | 0.52 | IGFBPL1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-6addd0cf |
| h-23e3985d | APOE4 Isoform Correction via Lipidation Enhancement as CTE Risk Mitigation | 0.55 | 0.85 | APOE | proposed | 2026-04-14 | SDA-2026-04-14-gap-pubmed-20260410-185318-186b0446 |
| h-1333080b | P2RX7-Mediated Exosome Secretion Blockade | 0.55 | 0.70 | P2RX7 | promoted | 2026-04-12 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| h-0b5a6761 | MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CNS-Penetrant Pro-Reso | 0.55 | 0.68 | MFSD2A (SLC59A1) | promoted | 2026-04-13 | SDA-2026-04-12-gap-debate-20260410-113110-2059f65f |
| h-var-0162bdbc90 | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscilla | 0.55 | 0.71 | AQP4 | promoted | 2026-04-21 | SDA-2026-04-03-26abc5e5f9f2 |
| h-var-ce29b18697 | Temporal NLRP3 Inhibition During SPP1-Driven Microglial Activation Windows | 0.55 | 0.40 | NLRP3 | promoted | 2026-04-20 | SDA-2026-04-15-gap-pubmed-20260406-062118-e3613755 |
| h-var-e607efdac0 | Astrocytic SPP1 Modulation Through STAT3-Dependent Transcriptional Control | 0.55 | 0.40 | SPP1 | promoted | 2026-04-20 | SDA-2026-04-15-gap-pubmed-20260406-062118-e3613755 |
| h-27bc0569 | Liquid-Liquid Phase Separation Modifier Therapy | 0.55 | 0.55 | G3BP1 | proposed | 2026-04-02 | SDA-2026-04-01-gap-9137255b |
| h-var-5900d71273 | Gamma-Entrained PV Interneuron Networks Enable Precision p-tau217-Guided lncRNA | 0.55 | 0.39 | PVALB, CREB1, lncRNA-0021/lncRNA-9969 | promoted | 2026-04-20 | SDA-2026-04-26-gap-pubmed-20260410-150509-76c40dac-debate |
| h-ff019d4736 | Pentose Phosphate Pathway Suppression Enables Ferroptosis Vulnerability | 0.55 | 0.65 | G6PD, SLC7A11, GPX4 | proposed | 2026-05-03 | SDA-2026-05-03-gap-test-20260425-224949 |
| h-5a4efb713f | Astrocyte Reactivity Reprogramming via A1/A2 Phenotype Modulation | 0.55 | 0.62 | IL1A/TNF/C1Q | proposed | 2026-04-28 | SDA-2026-04-28-gap-test-20260425-224949 |
| h-analogy-ceb122df | TREM2-complement-amyloid axis as therapeutic target for protein aggregation diso | 0.55 | 0.45 | TREM2 | active | 2026-04-28 | |
| h-analogy-daabed82 | TREM2-Modulating LNPs for Neurodegeneration: Cell-Type-Specific Immunometabolic | 0.55 | 0.45 | TREM2 | active | 2026-04-28 | |